SVP, Medical Strategy and Development
mQOL
Blake Morrison, PharmD leads clinical development for mQOL. In his current capacity, Blake is leading the development and clinical validation of a new service to capture symptom and QoL monitoring data. He brings 30+ years of clinical practice and biopharmaceutical industry experience with a therapeutic area focus on hematology / oncology. His functional area of expertise is Clinical Development, Medical Affairs and Evidence Generation. Blake has experience in signal-finding drug development, HEOR / RWE, life cycle management, scientific communications and business development.
Blake has had successful ventures working for several leading biopharmaceutical firms and associated with multiple novel compound development efforts and commercial product launches. His experience includes executive leaderships roles at Turning Point Therapeutics (acquired by Bristol Myers Squibb), Karyopharm Therapeutics, Halozyme Therapeutics, Onyx Pharmaceuticals (acquired by Amgen), Genentech BioOncology, and Millennium Pharmaceuticals (acquired by Takeda).
Additionally, Blake has had recent experiences in the diagnostic and medical technology space. At ONCOtracker, he helped develop a newly identified biomarker for monitoring of multiple myeloma, and successfully out licensed the asset to a global diagnostic company. Similarly, he led the clinical and business development efforts for a newly developed MRD test.
Finally, Blake has a successful history in entrepreneurship and building new companies. He is co-founder and subject matter expert in MYELOMA360, an insight generation firm. He is also principal of venn5 BioConsulting, which focuses on start-up entities and provides ‘share of voice’ to the oncology community for new product developments.
Blake graduated with his Doctor of Pharmacy from the University of the Pacific and completed residencies in oncology and infectious diseases.